Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II comparison of dose-titration versus approved dosing of fulvestrant in hormone-responsive advanced breast cancer
2008-004988-19Phase 2Terminated
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of fulvestrant in breast cancer (2 arms), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Time to progression or death. Started Jan 2009; status: terminated.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-004988-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004988-19.